Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 28652249
Richer AL, et al. (2017) WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer. Cancer Res 77, 4663-4672 28652249
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S139-p - H2AX (human)
Modsite: GkkAtQAsQEy____ SwissProt Entrez-Gene
Orthologous residues
H2AX (human): S139‑p, H2AX (mouse): S139‑p, H2AX (rat): S139‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), NCI-H2030 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
AZD1775 decrease
AZD1775 cisplatin inhibit treatment-induced increase

T366-p - LKB1 (mouse)
Modsite: IEDGIIytQDFTVPG SwissProt Entrez-Gene
Orthologous residues
LKB1 (human): T363‑p, LKB1 iso2 (human): T363‑p, LKB1 (mouse): T366‑p, LKB1 (rat): T366‑p, LKB1 (pig): T271‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), NCI-H2030 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Downstream Regulation
Effect of modification (process):  apoptosis, inhibited
Comments:  improved survival of LKB1-deficient H2030 NSCLC cells to combined AZD1775 + cisplatin treatment